Information Provided By:
Fly News Breaks for May 22, 2017
PBYI
May 22, 2017 | 12:40 EDT
Credit Suisse analyst Alethia Young said she was surprised to find that the neratinib briefing documents posted ahead of Wednesday's FDA advisory committee meeting to discuss Puma Biotechnology's breast cancer treatment were "pretty clean" and contained "no big surprises." It seemed the documents were supportive of the efficacy and didn't provide much surprise on tolerability, though she is only "cautiously optimistic" while watching out for "any curveballs" when the panel meets, she tells investors. Young keeps an Outperform rating and $58 price target on Puma shares.
News For PBYI From the Last 2 Days
There are no results for your query PBYI
I agree to the thefly.com's disclaimer & terms of use
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.